Perfluoro-N-octane (PFO) in the repair of complicated retinal detachments due to severe proliferative diabetic retinopathy

Ophthalmic Surgery and Lasers

Volumn 30, Issue 9, 1999, Pages 715-720

  Maturi, Raj K ^a,f,g   Merrill, Pauline T ^a,b,f,g   Lomeo, Mark D ^a,c   Diaz Rohena, Roberta ^a   Khan, Myrna ^a   Lambert, H Michael ^a,d,e,h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Retina Group   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e Huffington Center on Aging   (United States)

^f Heed and Heed Knapp Foundation   (United States)

^g Research to Prevent Blindness Inc   (United States)

^h PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; PERFLUORO COMPOUND; PERFLUOROOCTANE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REOPERATION; RETINA DETACHMENT; SURGICAL ANATOMY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; DIABETIC RETINOPATHY; FLUOROCARBONS; HUMANS; INJECTIONS; INTRAOPERATIVE PERIOD; LASER COAGULATION; MIDDLE AGED; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 0032720976     PISSN: 10823069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Peyman GA, Schulman AJ, Sullivan B. Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol. 1995;39: 375-395.
2. Chang S, Ozmert E, Zimmerman NJ. Intraoperative perfluorocarbon liquids in the management of proliferative vitreoretinopathy. Am J Ophthalmol. 1988;106:668-674.
3. Coll GE, Chang S, Sun J, Wieland MR, Berrocal MH. Perfluorocarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1995;102:630-639.
4. Glaser BM, Carter JB, Kupermann BD, Michels RG. Perfluorooctane in the treatment of giant retinal tears with proliferative vitreoretinopathy. Ophthalmology. 1991;98:1613-1621.
5. Chang S, Sparrow JR, Iwamoto T, et al. Experimental studies of tolerance to intravitreal perfluoro-n-octane liquids in the management of proliferative vitreoretinopathy. Am J Ophthalmol. 1988;107:761-766.
6. Moreira H, de Queiroz JM Jr, Liggert PE, McDonnell PJ. Corneal toxicity study of two perfluorocarbon liquids in rabbit eyes. Cornea. 1992;11:376-379.
7. Mathis A, Pagot V, David JL. The use of perfluorodecalin in diabetic vitrectomy. Fortschritte der Ophthalmology. 1991;88:148-150.
8. Corcostegui B. Use of perfluorocarbon liquid in vitrectomy for diabetic rhegmatogenous retinal detachment. Journal of Vitreoretina. 1992;1:30-37.
9. Pearson RV, McLeod D, Gregor ZJ. Removal of silicone oil following diabetic vitrectomy. Br J Ophthalmol. 1993;77:204-207.
10. Thompson IT, de Bustros S, Michaels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. 1987;105:497-502.
11. Thompson IT, de Bustros S, Michaels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction-rhegmatogenous retinal detachment. Arch Ophthalmol. 1987;105:503-507.
12. Brown GC, Tasman WS, Benson WE, et al. Reoperation following diabetic vitrectomy. Arch Ophthalmol. 1992;110:506-510.
13. Mathis A, Pagot V, Idder A, Malecaze F. Use of perfluorodecalin during vitrectomy in diabetics. J F Ophthalmol. 1993;16:584-590.